Symbicort [budesonide/formoterol] in chronic obstructive pulmonary disease

Trial Profile

Symbicort [budesonide/formoterol] in chronic obstructive pulmonary disease

Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2008

At a glance

  • Drugs Budesonide/formoterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms SYMBIOSE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 19 Mar 2008 QA'ed
    • 14 Mar 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top